Bicuspid Aortic Valve Clinical Trial
Official title:
NavIIcusp: Bicuspid Aortic Valve Stenosis With Navitor Platform International Experience
The aim of this prospective registry is to evaluate the clinical impact of the new Navitor prosthesis (Abbott, Minneapolis, MN, USA) in BAV and evaluate both the main sizing methods (the classical annular or the supra-annular with ICD measurement at 4 mm above the virtual basal ring).
Status | Not yet recruiting |
Enrollment | 150 |
Est. completion date | May 1, 2026 |
Est. primary completion date | May 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years. 2. NYHA = 2 and/or syncope and/or angina. 3. Symptomatic severe calcified aortic stenosis with AVA < 1 cm2 AND peak velocity > 4 m/s or mean gradient > 40 mmHg or DVI < 0.25'. 4. Patient judged by the Heart Team as indicated for TAVI. 5. Anatomical suitability for transfemoral-TAVI with Navitor, based on MSCT assessment. 6. Estimated life-expectancy > 1 year. Exclusion Criteria: 1. Age < 18 years 2. Asymptomatic patients 3. Estimated life expectancy < 1 year 4. Pure aortic regurgitation. 5. LVEF < 20% 6. No baseline MSCT evaluation. 7. Unsuitable aortic root anatomy for Navitor. 8. Unsuitable peripheral vasculature for transfemoral Navitor. 9. Type 2 bicuspid aortic valve 10. Excessive leaflet calcifications 11. Moderate or severe raphe calcifications 12. Severe LVOT calcifications 13. Perimeter-derived annular dimension exceeding IFU recommendation 14. Dilated ascending aorta >45 mm |
Country | Name | City | State |
---|---|---|---|
France | Clinique Pasteur | Toulouse | Occitanie |
Lead Sponsor | Collaborator |
---|---|
Didier TCHETCHE | Abbott |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 30-day device success (Rate) | as indicated in the VARC-3 criteria | 30-day | |
Secondary | 1 year at least moderate bioprosthetic valve deterioration | defined as increase in mean transvalvular gradient =10 mmHg resulting in mean gradient =20 mmHg with concomitant decrease in EOA =0.3 cm2 or =25% and/or decrease in Doppler velocity index =0.1 or =20% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence or increase of =1 grade of intra-prosthetic AR resulting in = moderate AR | 1-year | |
Secondary | 1 year severe patient-prosthesis mismatch | defined as EOAi < 0.65 cm2/m2 | 1-year | |
Secondary | 30 days and 1 year all-cause and cardiovascular mortality | 1-year | ||
Secondary | 30 days and 1 year stroke | 1-year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01390181 -
The Effect of Losartan in Bicuspid Aortic Valve Patients
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Active, not recruiting |
NCT03635424 -
Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study
|
N/A | |
Recruiting |
NCT06153407 -
Genetic Test Based Risk Prediction of Early Calcific Aortic Valve Disease in Patients With Bicuspid Aortic Valve
|
||
Active, not recruiting |
NCT03474159 -
Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve by Multimodal Imaging
|
N/A | |
Recruiting |
NCT05739253 -
Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement
|
||
Completed |
NCT01823432 -
Genetic Risks for Bicuspid Aortic Valve Disease
|
||
Completed |
NCT02679261 -
Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve
|
Phase 3 | |
Completed |
NCT01920815 -
Bicuspid Valve Aortopathy Feasibility Study
|
||
Recruiting |
NCT04817735 -
The CASPER Registry
|
N/A | |
Recruiting |
NCT02899624 -
Whole Exome Sequencing in Bicuspid Aortic Valve Patients
|
N/A | |
Recruiting |
NCT05708118 -
Progression of Ascending Aorta Diameters in Bicuspid Aortic Valve After Transcatheter or Surgical Replacement.
|
||
Recruiting |
NCT03495050 -
BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.
|
||
Completed |
NCT01760668 -
Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome
|
N/A | |
Not yet recruiting |
NCT05711693 -
Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)
|
N/A | |
Completed |
NCT05836363 -
Fate at Long-term of Mild to Moderate Bicuspid Aortic Valve Disease Left Untreated at the Time of Supracoronary Ascending Aorta Replacement
|
||
Completed |
NCT02283970 -
Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)
|
||
Active, not recruiting |
NCT01026571 -
Identification of Genetic Causes of Bicuspid Aortic Valve Disease
|
||
Completed |
NCT00412386 -
Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve
|
N/A | |
Recruiting |
NCT03440697 -
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
|